Predict your next investment

HEALTHCARE | Biotechnology
iota.bio

See what CB Insights has to offer

Founded Year

2017

Stage

Acquired | Acquired

Total Raised

$15M

About Iota Biosciences

Iota Biosciences aims to change how the world monitors and treats disease. Building on 'neural dust' technology, it is building a platform for the future of bioelectronic medicine.On October 15, 2020 Iota Biosciences was acquired by Astellas Pharma at a valuation of $127.5M to acquire the remainder of shares.

Iota Biosciences Headquarter Location

1936 University Ave Suite 355

Berkeley, California, 94704,

United States

Latest Iota Biosciences News

Merger Agreement for Astellas Pharma Inc and iota Biosciences

Oct 19, 2020

Pharmafield By Astellas Pharma Inc. and iota Biosciences, Inc. have announced that Astellas, through a U.S. subsidiary, and iota have entered into a Merger Agreement , with Astellas acquiring iota. Pharmaceutical company Astellas is currently promoting the Focus Area Approach, which is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. iota’s innovative technology uses ultrasound both to power the devices and to enable wireless communication. This resulted in the ability to develop unprecedentedly ultra-small (millimeter sized) battery-free, wireless implantable medical devices. Astellas and iota previously entered into a Research and Development Agreement in August 2019 (the “R&D Agreement”) to jointly conduct research and development activities associated with iota’s ultrasonic-powered bioelectronic devices (also known as ‘neural dust’) in a number of indications. In carrying out the activities contemplated under the R&D Agreement, the companies have evaluated detailed specifications for implantable medical devices focused on multiple diseases with high unmet medical needs. This Merger Agreement, which contemplates the utilization of iota’s unique technology as a platform to advance innovation in the bioelectronics field, is expected to accelerate Astellas’ Rx+® business not only by expediting the Rx+® projects previously covered under the R&D Agreement but also by allowing exploration of other applications of iota’s unique bioelectronics technology for new target diseases and developing new  technologies. Conventional implantable medical devices require batteries for power supply and wires or large electronic circuits to facilitate communications. This has made size reduction difficult and has often resulted in highly invasive implant procedures. In contrast, iota’s bioelectronic devices can be implanted through a less invasive operative procedure and offer promise for a new healthcare solution with improved effectiveness and reduced physical burden for the patients during and after surgery. Since the signing of the R&D Agreement last year, the companies have advanced joint research and development by leveraging respective strengths of the parties: iota with its core technology and world-class talent in the field of bioelectronics and Astellas with its expertise and deep understandings in biology and diseases as well as experiences in advancing medical solutions from research to market. Clinical trials of multiple projects including those under the R&D Agreement are expected to start in the early 2020s. Kenji Yasukawa, Ph.D., President and CEO, Astellas said: “I believe that iota’s technology is a promising core technology that can be applied not only to the current programs we are working on, but to broader types of diseases that have yet to be worked on. I expect that the combination of their capabilities with our strength cultivated through our Rx business will become a strong basis to further drive our Rx+® business.” Michel Maharbiz, Ph.D. and Jose Carmena, Ph.D., Co-founders and Co-CEOs, iota said: “The partnership between iota Biosciences and Astellas allows us to combine our respective strengths to bring revolutionary new approaches to managing and treating diseases that affect hundreds of millions of people across the world. A new era in bioelectronic medicine is dawning and iota Biosciences, powered by Astellas, will be leading the charge.” TAGS

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Iota Biosciences

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Iota Biosciences in 1 CB Insights research brief, most recently on Aug 6, 2020.

Expert Collections containing Iota Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Iota Biosciences is included in 5 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

M

Medical Devices

8,341 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharmaceuticals

5,726 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

B

Bioelectronics

819 items

Companies developing/using technology aimed at detecting, interpreting, interrupting, eliciting, or redirecting electrical signals within the body

H

Health & Wellness Assessment Tools

2,094 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes providers.

Iota Biosciences Patents

Iota Biosciences has filed 2 patents.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Clusters of differentiation
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/19/2019

6/15/2021

Implants (medicine), Peripheral nervous system disorders, Neurophysiology, Neurotechnology, Neuroprosthetics

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

4/19/2019

00/00/0000

Grant Date

6/15/2021

00/00/0000

Title

Subscribe to see more

Related Topics

Implants (medicine), Peripheral nervous system disorders, Neurophysiology, Neurotechnology, Neuroprosthetics

Subscribe to see more

Status

Grant

Subscribe to see more

Iota Biosciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Iota Biosciences Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.